Indian pharma exports hit
The West Asia crisis is disrupting Indian pharma exports and driving calls for a ‘Health Security Corridor’ to protect supply lines to Latin America, Southeast Asia and East Africa — a direct risk to finished‑drug and ingredient availability. Industry groups warn that higher freight costs and rerouted logistics are already raising input lead times and pushing manufacturers to seek alternative routing and local safeguards. (firstpost.com)
Pharmexcil (Pharmaceuticals Export Promotion Council of India) warned a complete stop to pharma shipments this month could erase between Rs 2,500 crore and Rs 5,000 crore in export value, citing the squeeze on Gulf routes. (indiashippingnews.com) Freight carriers and shippers are imposing surcharges of roughly $4,000–$8,000 per shipment as vessels divert around the Red Sea/Strait of Hormuz and airspace restrictions push slower, longer routings. (news18.com) Gulf Cooperation Council markets accounted for about 5.58% of India’s pharma exports, while total Indian pharma exports stood at approximately $30.38 billion in the most recent fiscal year. (telanganatoday.com) Industry briefings and trade reports show exports to the WANA region have risen (from $1.32 billion in FY21 to $1.75 billion in FY25), increasing the absolute exposure that higher freight and insurance costs now threaten. (moneycontrol.com) Multiple trade bodies and logistics analysts are urging prepositioning of inventory and market diversification toward Southeast Asia, East Africa and Latin America while formally proposing a government-backed “Health Security Corridor” to protect critical medical shipments. (firstpost.com) Manufacturers report growing pressure on APIs and key starting materials, with supply-line stress and rising insurance premiums already cited as drivers of input-cost escalation; analysts warn supply chains would be materially strained if the conflict persists beyond 10–15 days. (journalofsupplychain.com) Freight-rate doubling and per-shipment surcharges increase landed costs and extend lead times, forcing exporters to tie up more working capital in buffer stock and potentially reducing short-term export margins that underpin the Rs 2,500–5,000 crore risk estimate. (news18.com)
